Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
HUMAN IMMUMOGLOBULINS
Instituto Grifols S.A.
50 g/l
Solution for Infusion
2000-03-08
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0849/004/001 Case No: 2070717 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to INSTITUTO GRIFOLS S.A. CAN GUASCH 2, PARETS DEL VALLES 08150, BARCELONA, SPAIN an authorisation, subject to the provisions of the said Regulations, in respect of the product FLEBOGAMMA 5% SOLUTION FOR INFUSION. HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS ADMINISTRATION. the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 08/03/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 24/08/2010_ _CRN 2070717_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flebogamma 5%. Solution for Infusion. Human Normal Immunoglobulin for Intravenous Administration. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (IVIg) The percentage of IgG subclasses is approximately 68.7% IgG 1 , 25.9% IgG 2 , 3.7% IgG 3 and 1.78% IgG 4 . Human protein content is 50 g/l of which at least 97% is IgG. IgA content is lower than 0.05 mg/ml. For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion Solution is clear or slightly opalescent and colourless or pale yellow. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC IND Lesen Sie das vollständige Dokument